Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.39 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | ITGAL | P20701 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7187697 | 0.91 | FABP3 (0.48) | FABP3FABP4TYK2TRPM4ITGB1 | |
| SCHEMBL7179685 | 0.90 | ALDH1A1 (0.48) | FABP3FABP4TYK2ALDH1A1KMT2A | |
| SCHEMBL7175322 | 0.89 | TYK2 (0.41) | FABP3FABP4TYK2TRPM4ALDH1A1 | |
| SCHEMBL7183622 | 0.88 | L3MBTL1 (0.40) | FABP3FABP4ALDH1A1HDAC4CYP2C9 | |
| SCHEMBL7174576 | 0.88 | ALDH1A1 (0.50) | FABP3FABP4TYK2ALDH1A1KMT2A | |
| SCHEMBL7185568 | 0.87 | FABP3 (0.40) | FABP3FABP4TYK2TRPM4KMT2A | |
| SCHEMBL27437106 | 0.86 | L3MBTL1 (0.41) | FABP3FABP4ALDH1A1HDAC4CYP2C9 | |
| SCHEMBL7182835 | 0.84 | FABP3 (0.43) | FABP3FABP4TYK2TRPM4ALDH1A1 | |
| SCHEMBL7182030 | 0.84 | KMT2A (0.41) | TYK2ALDH1A1KMT2APTGS2LMNA | |
| SCHEMBL7180462 | 0.83 | TYK2 (0.44) | FABP3FABP4TYK2TRPM4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | FABP3 3252/4885FABP4 4550/4885TYK2 1285/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | FABP3 2807/4885FABP4 4256/4885TYK2 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.